泼尼松联合阿达木单抗或环孢素对VKH皮肤病学症状的影响:随机试验的系统性结局
该研究利用VKH眼病试验的辅助数据,纳入接受个体化泼尼松减量(最大日剂量40 mg,最长6个月)的患者,随机加用阿达木单抗(N=54)或环孢素(N=56),评估第6个月白癜风、白发和脱发的改变。总体脱发比例下降,但白癜风或白发存在无变化;阿达木单抗组在受累皮肤病学类别数量的减少上优于环孢素组,各皮肤病表现百分比变化无名义显著差异。
要点
- 泼尼松减量联合阿达木单抗或环孢素均改善VKH脱发,但对白癜风和白发无明确效果。
- 阿达木单抗较环孢素更显著减少受累皮肤病学类别数量。
- 本研究为眼病试验的二次分析,6个月随访可能不足以评估白癜风和白发。
核心结论
- 泼尼松减量联合阿达木单抗或环孢素均相似地改善脱发,但6个月时对白癜风或白发存在无明显效果。
- 阿达木单抗与环孢素相比,与受累皮肤病学疾病数量的更大减少相关。
研究设计与样本
- 利用VKH眼病试验的辅助数据进行的二次分析。
- 患者接受个体化泼尼松减量(最大日剂量40 mg,最长6个月),随机加用阿达木单抗(N=54)或环孢素(N=56)。
- 结局包括第6个月时白癜风、白发和脱发的变化。
主要发现
- 总体而言,第6个月时脱发百分比下降,但白癜风或白发存在无变化。
- 阿达木单抗组各皮肤病学表现百分比变化无名义显著差异,但受累皮肤病学类别数量的减少大于环孢素组。
关键数值与推荐
- 泼尼松最大日剂量40 mg,最长持续时间6个月。
- 阿达木单抗组N=54,环孢素组N=56。
- 结局评估时间为第6个月。
临床怎么用
- 对于VKH相关脱发,泼尼松减量联合阿达木单抗或环孢素均可考虑。
- 阿达木单抗可能更有利于减少受累皮肤病学类别数量,但需结合眼病治疗综合决策。
局限性
- 本研究为VKH眼病试验的二次分析。
- 6个月随访可能无法充分评估对白癜风和白发的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vogt-Koyanagi-Harada (VKH) disease causes vitiligo, poliosis, and alopecia. OBJECTIVE: To investigate the effect of prednisone plus either adalimumab or cyclosporine-based immunosuppression on VKH dermatologic disorders using ancillary data from a VKH eye disease trial. METHODS: Patients with VKH disease treated with individualized prednisone tapering (maximum daily dose, 40 mg; maximum duration, 6 months) were randomized to adjunctive adalimumab (N = 54) or cyclosporine (N = 56). Outcomes included changes in vitiligo, poliosis, and alopecia at the sixth month. RESULTS: Overall, there was a decrease in the percentage of alopecia but no change in the presence of vitiligo or poliosis at the sixth month. The adalimumab group showed no nominally significant differences in the percentage changes of each dermatologic manifestation but a greater reduction in the number of affected dermatologic categories compared with the cyclosporine group. LIMITATIONS: This is a secondary analysis of a VKH eye disease trial. Six-month follow-up may not fully assess effects on vitiligo and poliosis. CONCLUSIONS: In conjunction with prednisone tapering, both adalimumab and cyclosporine similarily improved alopecia but had no obvious effect on the presence of vitiligo or poliosis at 6 months. Adalimumab was associated with a greater decrease in the number of affected dermatologic conditions compared with cyclosporine.
引用
- Zhong Z, Wang J, Liao W, et al. Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: Systemic outcomes from a randomized trial. J Am Acad Dermatol. 2025. PMID: 40043888. doi:10.1016/j.jaad.2025.02.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。